Why GSK stock is moving today: Exdensur EU nod and a fresh buyback
GSK shares rose 1.1% to 2,263 pence after the European Commission approved its twice-yearly asthma drug Exdensur and the company launched a new tranche of share buybacks. GSK will repurchase up to £0.45 billion in shares by April 24. The company also reported new real-world data showing its RSV vaccine Arexvy was 75.6% effective against RSV-related hospitalisation in adults over 60.